SCHEMBL15020926

SCHEMBL15020926

CCOCc1nn2c(-c3cccc(F)c3)cc(N3CCCC3CO)nc2c1-c1ccc(Cl)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FPR2 P25090 1/20 0.36
▸ SCN9A Q15858 1/20 0.36
▸ CHRM3 P20309 2/20 0.34
▸ CDK1 P06493 3/20 0.33
▸ PRKCA P17252 1/20 0.33
▸ SYK P43405 1/20 0.33
▸ BCL6 P41182 1/20 0.33
▸ CRHR1 P34998 1/20 0.33
▸ SPHK2 Q9NRA0 2/20 0.33
▸ SPHK1 Q9NYA1 2/20 0.33
▸ LMNA P02545 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ IRAK4 Q9NWZ3 1/20 0.32
▸ SOS1 Q07889 2/20 0.32
▸ ITGB2 P05107 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15021293 0.93 FPR2 (0.37) FPR2SCN9ACHRM3SYKBCL6
SCHEMBL15020764 0.92 FPR2 (0.37) FPR2SCN9ACHRM3CDK1PRKCA
SCHEMBL15020543 0.92 FPR2 (0.37) FPR2SCN9ACHRM3CDK1PRKCA
SCHEMBL15020756 0.92 FPR2 (0.41) FPR2SCN9ACHRM3CDK1PRKCA
SCHEMBL15020757 0.92 FPR2 (0.39) FPR2SCN9ACDK1SYKSPHK2
SCHEMBL15020794 0.91 MEN1 (0.40) FPR2SCN9ACHRM3CDK1PRKCA
SCHEMBL15020889 0.88 KDM4E (0.36) FPR2SCN9ACDK1SYKALDH1A1
SCHEMBL15020939 0.87 TP53 (0.46) FPR2SCN9ASYKCRHR1LMNA
SCHEMBL15020577 0.86 KDM4E (0.38) FPR2SCN9ACHRM3SYKBCL6
SCHEMBL15020887 0.85 FPR2 (0.42) FPR2SCN9ABCL6LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 — — US claimed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 — — EP claimed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 — — US claimed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 — — US disclosed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 — — EP disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR CNR1, CNR2, GPR18 FPR2 2908/4885SCN9A 615/4885CHRM3 1917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback